Palisade Bio, Inc. PALI
1.15 USD -0.02 (-1.78%)
Nov 12, 2026, 2:11 PM EST
1.13 Day range 1.18
1.08 52-week range 2.86
- YTD
- -51.10%
- 1 year
- -43.67%
News
benzinga.com Palisade Bio Analysts Slash Their Forecasts After Q3 Results Palisade Bio, Inc. (NASDAQ:PALI) reported a wider-than-expected loss for the third quarter on Tuesday.
benzinga.com Palisade Bio Analysts Slash Their Forecasts After Q3 Results Palisade Bio missed Q3 loss estimates at 7¢/share. Shares rose 3.1% as analysts cut price targets; ASCENTRA trials advance.
benzinga.com Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16 Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.
benzinga.com HC Wainwright & Co. Maintains Buy on Palisade Bio, Lowers Price Target to $5 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Palisade Bio (NASDAQ:PALI) with a Buy and lowers the price target from $7 to $5.
benzinga.com Palisade Bio Q3 EPS $(0.07) Misses $(0.06) Estimate Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 81.58 percent increase over losses of…
globenewswire.com Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New…- benzinga.com Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027 PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of…
benzinga.com Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The…- benzinga.com HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
benzinga.com Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo…
benzinga.com Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6 Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.
benzinga.com Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic…
benzinga.com Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic- benzinga.com HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
- benzinga.com Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic…
benzinga.com ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.- benzinga.com Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same…
benzinga.com This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.- benzinga.com Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8 Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.
- benzinga.com Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative Colitis ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and EuropeFirst patient enrollment anticipated in the second half of 2026;…
- benzinga.com Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis Symposium Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approachDenver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio,…
benzinga.com Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include…- benzinga.com Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 89.36 percent increase over losses of $(0.47)…
benzinga.com Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026 Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing intervalSteady-state pharmacokinetic findings provide mechanistic…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Palisade Bio's Data From Its Lead Program, PALI-2108, Selected For Poster Presentation At Digestive Disease Week 2026 Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDTDenver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage…- benzinga.com Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7 Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
- benzinga.com Palisade Bio Announces Topline Data From Phase 1b Clinical Study Evaluating PALI-2108, Once-Daily Oral PDE4 Inhibitor Prodrug To Be Selectively Bioactivated In Ileum And Colon, In Patients With FSCD PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic…
- benzinga.com HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
benzinga.com This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Stifel Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $5 Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $5.
- benzinga.com Palisade Bio Announces Presentation Of New Translational Data For PALI-2108 At 21st Congress Of ECCO In Stockholm Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven daysEncouraging…
- benzinga.com Palisade Bio Two Abstracts Selected For Poster Presentation At Two Premier International Inflammatory Bowel Diseases Meetings Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted…
- benzinga.com B. Riley Securities Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7 B. Riley Securities analyst William Woods initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
- benzinga.com Palisade Bio Secures Up To $500K Strategic Investment From The Crohn's & Colitis Foundation, To Advance PALI-2108 For Ulcerative Colitis And Fibrostenotic Crohn's Disease PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and…
benzinga.com Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - benzinga.com Clear Street Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $12 Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $12.
- benzinga.com Palisade Bio Secures Japan Patent For PALI-2108 For Ulcerative Colitis And Fibrostenotic Crohn's Disease PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) to address…
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - benzinga.com Piper Sandler Initiates Coverage On Palisade Bio with Overweight Rating, Announces Price Target of $25 Piper Sandler analyst Yasmeen Rahimi initiates coverage on Palisade Bio (NASDAQ:PALI) with a Overweight rating and announces Price Target of $25.
benzinga.com Why Bolt Projects Holdings Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket 
benzinga.com Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Palisade Bio Q3 EPS $(0.38) Misses $(0.27) Estimate Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.27) by 39.19 percent. This is a 83.62 percent increase over losses of…
- benzinga.com Palisade Bio Doses The First Patients In Its Phase 1b Study Of PALI-2108, A First-In-Class Ileocolonic-Targeted PDE4 Inhibitor Prodrug For Fibrostenotic Crohn's Disease—A Condition With No Approved Therapies First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, PK, and PD data anticipated in Q1 2026Advances ongoing…
- benzinga.com Palisade Bio Secures Canadian Patent For PALI-2108, Gut-Activated PDE4 B/D Inhibitor Targeting FSCD And UC PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical…
benzinga.com Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and is investing in this biotech firm...
benzinga.com Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session